Zolmitriptan

Summary

Zolmitriptan (CHEMBL1185) is an approved small-molecule serotonergic agonist (ATC N02CC03) targeting HTR1A, HTR1B, and HTR1D; indicated across 1 condition including migraine disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02CC03
• Targets: 5 (HTR1A, HTR1B, HTR1D…)
• Indications: 1 condition
• Clinical trials: 10
• Chemistry: 287.36 Da · C16H21N3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1185
Name	Zolmitriptan
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	60857
ChEBI	CHEBI:10124
ATC	N02CC03
Molecular formula	C16H21N3O2
Molecular weight	287.36
InChIKey	ULSDMUVEXKOYBU-ZDUSSCGKSA-N

SMILES: CN(C)CCC1=CNC2=C1C=C(C=C2)C[C@H]3COC(=O)N3

IUPAC name: (4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one

ChEBI definition: A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.

Pharmacological roles (ChEBI): serotonergic agonist, vasoconstrictor agent, anti-inflammatory drug.

Also known as: 311C90, Cvt-427, NSC-760383, Zolmitriptan, Zomig, Zomig-zmt, ZOLMITRIPTAN, zolmitriptan, SID144205008, SID170464875, ZolmitriptanÊ, ZolmitriptanÂ

Patent coverage: 3,438 distinct patent families (13,569 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 13,370 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR1A	5-HT1A receptor	Full agonist	6.6	0%	P08908
HTR1B	5-HT1B receptor	Partial agonist	7.7	0.2%	P28222
HTR1D	5-HT1D receptor	Full agonist	8.9	0%	P28221
HTR1E	5-ht1e receptor	Full agonist	7.7	0%	P28566
HTR1F	5-HT1F receptor	Full agonist	7.5	0.1%	P30939

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 1D, Adrenergic receptor alpha-2, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, Alpha-1A adrenergic receptor, D(1A) dopamine receptor, D(2) dopamine receptor.

Bioactivity

ChEMBL activities: 17 potent at pChembl ≥ 5 of 20 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P61169	10.4	Kd	0.04	nM	CHEMBL_ACT_1007292
P18901	9.52	Kd	0.3	nM	CHEMBL_ACT_1007291
HTR1B	9.4	Ki	0.4	nM	CHEMBL_ACT_25553867
HTR1D	9.4	Ki	0.4	nM	CHEMBL_ACT_25553872
HTR1D	9.12	Ki	0.76	nM	CHEMBL_ACT_425320
HTR1D	9.04	Ki	0.92	nM	CHEMBL_ACT_450525
HTR1D	8.82	Kd	1.5	nM	CHEMBL_ACT_1007288
HTR1B	8.82	Kd	1.5	nM	CHEMBL_ACT_1007289
HTR1A	8.74	Kd	1.8	nM	CHEMBL_ACT_1007287
HTR1D	8.55	IC50	2.82	nM	CHEMBL_ACT_362928
HTR1D	8.4	Ki	4	nM	CHEMBL_ACT_450526
HTR1B	8.38	Ki	4.2	nM	CHEMBL_ACT_425319
HTR1B	8.21	IC50	6.17	nM	CHEMBL_ACT_362927
P19328	8.15	Kd	7	nM	CHEMBL_ACT_1007290
HTR1B	7.8	EC50	15.7	nM	CHEMBL_ACT_425321
HTR1A	7.11	Ki	78.6	nM	CHEMBL_ACT_450527
HTR1A	6.91	Ki	124	nM	CHEMBL_ACT_425318

Target pathways

Aggregated over 5 target gene(s): HTR1A, HTR1B, HTR1D, HTR1E, HTR1F.

Top Reactome pathways

8 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	5	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
Signaling by GPCR	5	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
Class A/1 (Rhodopsin-like receptors)	5	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
Amine ligand-binding receptors	5	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
Serotonin receptors	5	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
GPCR ligand binding	5	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
GPCR downstream signalling	4	HTR1B, HTR1D, HTR1E, HTR1F
G alpha (i) signalling events	4	HTR1B, HTR1D, HTR1E, HTR1F

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	5
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5
chemical synaptic transmission	5
signal transduction	5
adenylate cyclase-activating G protein-coupled receptor signaling pathway	4
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	4
regulation of behavior	3
vasoconstriction	2
behavioral fear response	1
serotonin receptor signaling pathway	1
gamma-aminobutyric acid signaling pathway	1
positive regulation of cell population proliferation	1
regulation of serotonin secretion	1
regulation of vasoconstriction	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
migraine disorder	4	MONDO:0005277	MONDO:0005277

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE4	3
PHASE3	3
PHASE1	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00637286	PHASE4	COMPLETED	ZAP, US. Zomig for Appropriate for Primary Care
NCT01211145	PHASE4	COMPLETED	Zomig - Treatment of Acute Migraine Headache in Adolescents
NCT03145467	PHASE4	COMPLETED	Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine in Emergency Department
NCT00442936	PHASE3	COMPLETED	Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
NCT00617695	PHASE3	COMPLETED	Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
NCT00617747	PHASE3	COMPLETED	Efficacy and Tolerability of Zolmitriptan Nasal Spray
NCT02609945	PHASE1	COMPLETED	Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
NCT03978403	PHASE1	COMPLETED	A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers
NCT06074016	PHASE1	COMPLETED	Pharmacokinetics in Oral and Intranasal Formulations of Zolmitriptan.
NCT05019430	EARLY_PHASE1	COMPLETED	Cocaine and Zolmitriptan

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

415 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
ERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
IMIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
NARATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
RISPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
RIZATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
SUMATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
SEROTONIN	ChEMBL + PubChem	Phase 3 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
YOHIMBINE	ChEMBL + PubChem	Phase 3 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
MEBUFOTENIN	ChEMBL	Phase 2	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1E, HTR1F
ELETRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1E, HTR1F
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1E, HTR1F
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B, HTR1D, HTR1E
FROVATRIPTAN	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B, HTR1D, HTR1E
PSILOCIN	ChEMBL	Phase 2	HTR1A, HTR1B, HTR1D, HTR1E
CYPROHEPTADINE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1E, HTR1F
LASMIDITAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1D, HTR1E, HTR1F
METHYLERGONOVINE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1E, HTR1F
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1E
QUETIAPINE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1E, HTR1F
SORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1E, HTR1F
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B, HTR1D
AZELASTINE	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D, HTR1E
CARIPRAZINE	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B, HTR1D
KETANSERIN	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B, HTR1D
NEFAZODONE	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B, HTR1D
OXYMETAZOLINE	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B, HTR1D
SALMETEROL	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B, HTR1D
SILODOSIN	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B, HTR1D
VILAZODONE	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B, HTR1D
XYLOMETAZOLINE	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B, HTR1D
ACETRYPTINE	ChEMBL	Phase 2	HTR1A, HTR1B, HTR1D
GSK163090	ChEMBL	Phase 2	HTR1A, HTR1B, HTR1D
LYSERGIDE	ChEMBL	Phase 2	HTR1A, HTR1D, HTR1E
RITANSERIN	ChEMBL	Phase 2	HTR1A, HTR1B, HTR1E
ASENAPINE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1E
CANNABIDIOL	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1E
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	HTR1B, HTR1D
ZIPRASIDONE	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1E
CINACALCET	ChEMBL	Phase 4 (approved)	HTR1A, HTR1D
LOPERAMIDE	ChEMBL	Phase 4 (approved)	HTR1A, HTR1D
MIANSERIN	ChEMBL	Phase 4 (approved)	HTR1A, HTR1D
PINDOLOL	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B
PRAZOSIN	ChEMBL	Phase 4 (approved)	HTR1A, HTR1D
SERTINDOLE	ChEMBL	Phase 4 (approved)	HTR1A, HTR1B
TEGASEROD	ChEMBL	Phase 4 (approved)	HTR1A, HTR1D
LATREPIRDINE	ChEMBL	Phase 3	HTR1D, HTR1E
ALNIDITAN	ChEMBL	Phase 2	HTR1A, HTR1D
MAZAPERTINE	ChEMBL	Phase 2	HTR1A, HTR1B
NIGULDIPINE	ChEMBL	Phase 2	HTR1A, HTR1B
PENFLURIDOL	ChEMBL	Phase 2	HTR1A, HTR1D
SPIRAMIDE	ChEMBL	Phase 2	HTR1A, HTR1D
ACEMETACIN	ChEMBL	Phase 4 (approved)	HTR1A
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	HTR1A
ACETYLCHOLINE	ChEMBL	Phase 4 (approved)	HTR1A
ALMOTRIPTAN	ChEMBL	Phase 4 (approved)	HTR1A
AMILORIDE	ChEMBL	Phase 4 (approved)	HTR1A
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	HTR1A
AMLODIPINE	ChEMBL	Phase 4 (approved)	HTR1A